文献速递产科生殖医学

早期流产阴道米索前列醇与期待治疗的生育结局比较

Reproductive outcome after early miscarriage: comparing vaginal misoprostol treatment with expectant management in a planned secondary analysis of a randomized controlled trial.
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

本研究为随机对照试验的计划二次分析,比较早期流产女性期待治疗与阴道米索前列醇(单次800 µg)治疗后的生育结局。主要结局为完全流产后14个月内临床妊娠数及妊娠结局。两组临床妊娠率均为75%,活产率分别为40%和35%,差异无统计学意义。结论认为两种管理方式后生育力相似。

要点

  • 米索前列醇组与期待组14个月内临床妊娠率均为75%。
  • 米索前列醇组活产率40%,期待组35%,差异无统计学意义。
  • 米索前列醇组完全流产率85%,期待组65%。

核心结论

  • 早期流产女性接受米索前列醇治疗或期待管理后,生育力相似。

研究设计与样本

  • 随机对照试验的计划二次分析,比较期待管理与阴道米索前列醇(单次800 µg)治疗早期流产。
  • 米索前列醇组94例、期待组95例随机,分别94例和90例纳入分析。
  • 通过邮寄问卷及病历补充收集完全流产后14个月内的生育结局。

主要发现

  • 31天内无手术清宫达到完全流产:米索前列醇组85%(76/89),期待组65%(54/83)。
  • 手术清宫比例:期待组33%(27/83),米索前列醇组12%(11/89)。
  • 14个月内至少一次临床妊娠:米索前列醇组75%(67/89),期待组75%(62/83)。
  • 至少一次活产:米索前列醇组40%(36/89),期待组35%(29/83),平均差5.5%(95%CI -9.7至20.3%)。
  • 14个月内所有妊娠后活产:米索前列醇组63%(56/89),期待组55%(46/83),平均差7.5%(95%CI -7.9至22.4%)。

关键数值与推荐

  • 完全流产定义:31天内无手术清宫达到完全流产。
  • 米索前列醇方案:单次阴道给药800 µg。
  • 生育结局评估时间:完全流产后14个月内。

临床怎么用

  • 早期流产女性选择期待管理或米索前列醇治疗时,可告知两者后续生育力相似。
  • 米索前列醇组手术清宫率较低,完全流产率较高。

局限性

  • 为随机对照试验的二次分析,原始试验主要结局非生育结局。
  • 生育结局信息通过问卷获取,部分女性数据来自病历补充。
  • 样本量有限,置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the reproductive outcome after early miscarriage between women managed expectantly and those treated with vaginal misoprostol. METHODS: This study was a planned secondary analysis of data collected prospectively in a randomized controlled trial comparing expectant management with vaginal misoprostol treatment (single dose of 800 µg) in women with early embryonic or anembryonic miscarriage and vaginal bleeding. The outcome measures were the number of women with a clinical pregnancy conceived within 14 months after complete miscarriage and the outcome of these pregnancies in terms of live birth, miscarriage, ectopic pregnancy and legal termination of pregnancy. The participants replied to a questionnaire sent by post covering their reproductive history ≤ 14 months after the index miscarriage was complete. Supplementary information and data for women who did not return their questionnaire were retrieved from medical records. RESULTS: Of 94 women randomized to misoprostol treatment and 95 allocated to expectant management, 94 and 90 women, respectively, were included for analysis. Information on reproductive outcome was available for 89/94 (95%) and 83/90 (92%) women, respectively. Complete miscarriage without surgical evacuation was achieved within 31 days in 85% (76/89) of the women in the misoprostol group and in 65% (54/83) of those managed expectantly. The proportion of women treated with surgical evacuation was 33% (27/83) in the expectant-management group vs 12% (11/89) in the misoprostol group. At 14 months after the index miscarriage was complete, 75% (67/89) of women treated with misoprostol and 75% (62/83) of those managed expectantly had achieved at least one clinical pregnancy, while 40% (36/89) and 35% (29/83), respectively, had had at least one live birth (mean difference, 5.5% (95% CI, -9.7 to 20.3%)). When considering the outcome of all pregnancies conceived within 14 months after the index miscarriage was complete, 63% (56/89) of women in the misoprostol group and 55% (46/83) of those in the expectant-management group delivered a live baby after a pregnancy (mean difference, 7.5% (95% CI, -7.9 to 22.4%)). CONCLUSION: Women with early miscarriage can be reassured that fertility is similar after misoprostol treatment and expectant management. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Fernlund A, Jokubkiene L, Sladkevicius P, et al. Reproductive outcome after early miscarriage: comparing vaginal misoprostol treatment with expectant management in a planned secondary analysis of a randomized controlled trial. Ultrasound Obstet Gynecol. 2022. PMID: 34523740. doi:10.1002/uog.24769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。